Search Results
Your search for The ,The matches 33932 pages
Showing 3201 - 3250Expert Point of View: Joshua G. Cohen, MD
Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared his thoughts on the ADAGIO trial with The ASCO Post. He noted that uterine serous carcinoma—the...
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Highlights of the SGO 2023 Annual Meeting on Women’s Cancer
The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...
An Incidental Finding of Cancer Likely Saved My Life
Except for a ganglion cyst that had mysteriously popped up on the palm of my right hand in the winter of 2016, I appeared to be in excellent health. I had never had any serious illnesses in my then 55 years and rarely even got colds. If the annoying cyst hadn’t interfered with my normal daily...
City of Hope Appoints New Director and Chief Scientific Officer
City of Hope recently announced the appointment of John D. Carpten, PhD, as Director of the National Cancer Institute (NCI)-designated comprehensive cancer center, Director of Beckman Research Institute of City of Hope, and Chief Scientific Officer. Dr. Carpten will also hold the Irell &...
Personalized Mind-Body Medicine in Integrative Oncology
Guest Editor’s Note: Substantial evidence supports the value of practices that focus on the interactions among the mind, body, and behavior for promoting health and well-being. In this article, Kavita K. Mishra, MD, MPH, summarizes a clinical model for personalized mind-body medicine in cancer care ...
ED Visits Among Patients With Cancer: Three Main Messages
There are “three main messages” to be gleaned from a study about emergency department visits and unplanned hospitalizations among patients with cancer, the study’s lead author, Amir Alishahi Tabriz, MD, PhD, MPH, told The ASCO Post. Dr. Alishahi is Assistant Member, Department of Health Outcomes...
Study Finds Cancer-Related Emergency Department Visits Increased by 67%, Mainly Because of Uncontrolled Pain
Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...
Cancer Immunology and Immunotherapy: Principles and Practice
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, we begin a new series of articles on cancer immunology and immunotherapy, in which the authors discuss how immunotherapy has become a major pillar of...
Enfortumab Vedotin-ejfv With Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
On April 3, 2023, enfortumab vedotin-ejfv with pembrolizumab was granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy.1,2 Enfortumab vedotin-ejfv is an antibody-drug conjugate targeting nectin 4....
Detection of Early Emphysema During Lung Cancer Screening: Opportunities to Optimize Health
In an article in Annals of the American Thoracic Society, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Medicine, Rush University, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening...
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
Novel Hormone Receptor–Driven Therapies Tackling Endocrine Resistance in Breast Cancer
In hormone receptor–positive metastatic breast cancer, tumors eventually become resistant not only to endocrine blockade but to inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6). This obstacle to successful treatment is being tackled with novel hormone receptor–directed therapies, with the...
AACR Announces Fellows of the AACR Academy Class of 2023
The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. Fellows of the AACR Academy serve as a global brain trust of top contributors to cancer science and medicine who help advance the mission of the AACR to prevent and cure...
Expert Point of View: Jarushka Naidoo, MBBCh, MHS
Invited discussant Jarushka Naidoo, MBBCh, MHS, Professor of Medical Oncology and Consultant Medical Oncologist, Beaumont RCSI Cancer Centre, in Dublin, called the results of amivantamab-vmjw therapy in patients with EGFR exon 20 insertion–positive advanced non–small cell lung cancer (NSCLC)...
Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions
Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging long-term benefits and consistent efficacy in patients with advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions, according to data presented by Pilar Garrido, MD, PhD, Associate...
Expert Point of View: Daniel SW Tan, BSc, MBBS, PhD
Invited discussant of the phase II APPLE trial, Daniel SW Tan, BSc, MBBS, PhD, of the National Cancer Centre Singapore, noted that 17% of patients have had only molecular disease progression and were switched over to the sequential strategy. “This may be in some parts related to the sensitivity of...
Front-Line vs Sequential Use of Osimertinib in EGFR-Mutant NSCLC: Potential Impact of Liquid Biopsies
Using liquid biopsies to detect circulating tumor DNA (ctDNA) may soon transform treatment strategies for patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023 by lead study author Jordi Remon, MD, PhD, of...
Expert Point of View: Antonio Passaro, MD, PhD
Invited discussant Antonio Passaro, MD, PhD, of the European Institute of Oncology, Milan, Italy, underscored the significant results of the landmark CheckMate 816 trial, which he said, “established a new treatment paradigm for resectable NSCLC [non–small cell lung cancer].” In addition to the 14% ...
CheckMate 816: 3-Year Update Shows Improved Event-Free Survival With Neoadjuvant Nivolumab and Chemotherapy for Resectable NSCLC
The combination of neoadjuvant nivolumab plus chemotherapy continues to demonstrate potential as a standard treatment for patients with resectable non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023.1 The 3-year update from the phase III...
Expert Point of View: Jarushka Naidoo, MBBCh, MHS
The invited discussant for the CodeBreaK 200 trial, Jarushka Naidoo, MBBCh, MHS, Professor of Medical Oncology and Consultant Medical Oncologist at Beaumont RCSI Cancer Centre in Dublin, underscored the importance of patient-reported outcomes in evaluating the effectiveness of oncology treatments,...
CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients With Previously Treated NSCLC
The latest research on sotorasib, a targeted therapy for KRAS G12C–mutated non–small cell lung cancer (NSCLC), reveals that patients may experience better quality of life while benefiting from improved clinical outcomes. Analysis of patient-reported outcomes presented during the European Lung...
Olivier Delattre, MD, PhD, Honored With 2023 AACR–St. Baldrick’s Foundation Award
The American Association for Cancer Research (AACR) presented Olivier Delattre, MD, PhD, with the 2023 AACR–St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research during the AACR Annual Meeting 2023 in April in Orlando, Florida. Dr. Delattre is Director of the...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Expert Point of View: Jaffer A. Ajani, MD
Jaffer A. Ajani, MD, Professor of Medicine in the Department of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, told The ASCO Post that obesity (defined as high body mass index of 30–39.9 kg/m2) is increasing around the globe; by 2035, more than 50% of adults will...
Study Reveals Link Between Obesity and Gastric Cancer Aggressiveness
A pioneering study from Israel has shed new light on the link between obesity and the aggressiveness of gastric cancer while demonstrating potential therapeutic targets for the disease. Results of the translational research, presented during the Society of Surgical Oncology (SSO) 2023 International ...
Expert Point of View: Margaret K. Callahan, MD, PhD
Formal discussant of the mRNA-4157-P201/KEYNOTE-942 trial, Margaret K. Callahan, MD, PhD, Research Director, Immunotherapeutics Program, Memorial Sloan Kettering Cancer Center, New York, agreed that finding an effective cancer vaccine has been challenging, and she is “cautiously optimistic” about...
Study Shows mRNA-Based Personalized Vaccine Plus Pembrolizumab Active in Melanoma for the First Time
The search for an effective cancer vaccine has been frustrating, but finally there may be light at the end of the tunnel. Adjuvant use of an investigational personalized mRNA vaccine (mRNA-4157) plus the PD-1 inhibitor pembrolizumab improved recurrence-free survival vs pembrolizumab alone in...
USPSTF Issues Draft Recommendation Statement on Screening for Breast Cancer: All Women Should Be Screened Every Other Year, Beginning at Age 40
On May 9, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 years (this is a B grade recommendation, meaning the USPSTF...
Marcus O. Butler, MD, on Uveal Melanoma: Tebentafusp and Evidence of Tumor Response
Marcus O. Butler, MD, of Toronto’s Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. Tebentafusp is a first-in-class novel bispecific protein, the first therapy to show superior overall...
Tucatinib Plus Trastuzumab in HER2-Positive, Refractory, RAS Wild-Type, Unresectable or Metastatic Colorectal Cancer
As reported in The Lancet Oncology by John H. Strickler, MD, and colleagues, the phase II MOUNTAINEER trial has shown the activity of the combination of tucatinib plus trastuzumab in patients with HER2-positive, chemotherapy-refractory, RAS wild-type, unresectable or metastatic colorectal cancer....
Pain Control for Localized Spine Metastases: Stereotactic Radiosurgery vs Conventional Radiotherapy
As reported in JAMA Oncology by Ryu et al, the phase III portion of the NRG Oncology/RTOG 0631 trial showed no benefit in pain relief with use of stereotactic radiosurgery (SRS) vs conventional external-beam radiotherapy (EBRT) in patients with one to three sites of vertebral metastases. Study...
Bariatric Surgery May Reduce Risk of Obesity-Related Cancers by More Than Half
Researchers have found that patients who are obese and undergo bariatric surgery may have a greater than 50% decreased incidence rate of obesity-related cancer compared with patients who did not have the weight-loss procedure, according to new findings presented by Chittajalu et al at Digestive...
Three New Studies Unveil Recent Developments in the Screening and Treatment of Biliary Tract Cancer and Colorectal Cancer
Researchers have revealed the impacts of several new developments in screening and treating patients with biliary tract cancer and colorectal cancer—including the development of patient-derived organoids to test chemotherapy response, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to...
Extension of Adjuvant Anastrozole After Initial Therapeutic Regimen in Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
In a Japanese phase III trial (AERAS) reported in the Journal of Clinical Oncology, Iwase et al found that an additional 5 years of adjuvant anastrozole after 5 years of anastrozole or tamoxifen followed by anastrozole was associated with improved disease-free survival vs no further anastrozole...
Does Stem Cell Transplantation Extend Survival in Patients With Advanced Cutaneous T-Cell Lymphomas?
In a French study (CUTALLO) reported in The Lancet, de Masson et al found that patients with advanced-stage cutaneous T-cell lymphomas who were able to undergo allogeneic hematopoietic stem cell transplantation (HSCT) had prolonged progression-free survival vs matched patients receiving...
The Role of Salpingectomy in Ovarian Cancer: Standard of Care or Targeted Therapy?
No one doubts the deadly nature of high-grade serous ovarian cancer. This histologic subtype is responsible for most ovarian cancer deaths, representing the eighth leading cause of cancer deaths in women worldwide and the fifth in the United States. Although there has been some progress in...
Lung Cancer Screening and Possible Unappreciated Benefits
Screening that reduces cancer mortality serves as a foundational element of impactful care for certain cancers. That said, harms related to screening deserve our attention—overdiagnoses; diagnostic odysseys that may be invasive, expensive, or even unintentionally harmful; overtreatment of diagnosed ...
Expert Point of View: Roy S. Herbst, MD, PhD
Invited discussant Roy S. Herbst, MD, PhD, Deputy Director of the Yale Cancer Center, New Haven, Connecticut, called this “a very exciting abstract exploring when surgery meets immunotherapy.” He commented: “NSCLC is a big disease, affecting 2 million or more people worldwide, and this is the tip...
AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC
Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy...
Natalie Moryl, MD, on Managing Pain in Patients With Cancer
Natalie Moryl, MD, of Memorial Sloan Kettering Cancer Center, discusses severe cancer pain, a medical emergency that should be addressed with immediate intervention. The treatment plan, Dr. Moryl says, should include making a pain diagnosis; addressing reversible causes of pain such as spinal cord...
Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy
Mansoor R. Mirza, MD, of Copenhagen’s Rigshospitalet, discusses phase III data from the ENGOT-EN6-NSGO/GOG-3031/RUBY study, which showed that, compared with carboplatin and paclitaxel alone, dostarlimab-gxly plus carboplatin and paclitaxel increased progression-free survival in patients with...
Enrollment Criteria for Multiple Myeloma Clinical Trials May Exclude Patients From Racial and Ethnic Minorities
The parameters set to determine which patients can enroll in clinical trials testing new multiple myeloma treatments may disproportionately exclude patients from racial and ethnic minority groups, according to a new study published by Kanapuru et al in the journal Blood. Background Multiple myeloma ...
Antibacterial Treatment May Resolve Acute Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Researchers have found that acute radiation dermatitis may involve the skin bacterium Staphylococcus aureus and that a simple, low-cost treatment may prevent severe cases in patients undergoing radiation therapy, according to two novel studies published by Kost et al—one a randomized clinical trial ...
Induction Failure in Pediatric and Young Adult Patients With T-Cell ALL
In an analysis reported in the Journal of Clinical Oncology, O’Connor et al found that pediatric and young adult patients with T-cell acute lymphoblastic leukemia (T-ALL) who did not respond to induction therapy had poorer outcomes vs those with induction response. The investigators also attempted...
Expert Point of View: Rachna T. Shroff, MD
Formal discussant of this trial at the American Association for Cancer Research Annual Meeting, Rachna T. Shroff, MD, Associate Professor, Interim Chief of Hematology/Oncology, and Associate Director of Clinical Investigations, University of Arizona Cancer Center, said: “This is a very important...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...
